{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:09:30Z","timestamp":1784045370735,"version":"3.55.0"},"reference-count":49,"publisher":"University of Toronto Press Inc. (UTPress)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Invest Med"],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>This meta-analysis examined the efficacy and safety of dexamethasone compared with prednisone in the treatment of acute lymphoblastic leukemia (ALL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A search was conducted in PubMed, EMBASE, and the Cochrane Library databases for randomized controlled trials (RCTs) or observational studies involving children diagnosed with ALL who received dexamethasone or prednisone\u00a0as pharmacotherapy. Studies without access to primary data were excluded. RCTs were assessed using the Cochrane Risk of Bias 2.0 tool, while observational studies were evaluated with ROBINS-I.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Fourteen studies involving 12,665 children were analyzed. Dexamethasone significantly improved event-free survival compared to prednisone (OR 1.40 [95% CI 1.26 to 1.56],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). However, the pooled results, which showed significant heterogeneity, indicated a potentially higher incidence of toxicity associated with dexamethasone (OR 1.92 [95% CI 1.32 to 2.81]), a finding that warrants cautious interpretation. Qualitative synthesis further clarified that this increased risk was particularly evident for infectious, neuropsychiatric, and musculoskeletal adverse events. No significant differences were found in remission rates, relapse rates, or mortality between the two glucocorticoids. The GRADE assessment indicated high certainty regarding the evidence for event-free survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In children with ALL, dexamethasone improves event-free survival compared to prednisone but may have a higher risk of adverse effects. This highlights the need for a careful benefit-risk assessment. Future research should explore hybrid glucocorticoid strategies to maximize survival outcomes while reducing adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3138\/cim-2025-0188","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:43:48Z","timestamp":1784043828000},"page":"43-55","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of dexamethasone and prednisone for therapy in childhood acute lymphoblastic leukemia: A systematic review and meta-analysis"],"prefix":"10.3138","volume":"49","author":[{"given":"Wenqiong","family":"Lv","sequence":"first","affiliation":[{"name":"Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China"},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China"},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China"},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Sichuan\u00a0Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of\u00a0China, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China"},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1696","reference":[{"issue":"10230","key":"e_1_3_10_2_2","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard F","year":"2020","unstructured":"Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395(10230):1146\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(19)33018-1","journal-title":"Lancet"},{"issue":"2","key":"e_1_3_10_3_2","first-page":"106","article-title":"Recent advances in adult acute lymphoblastic leukemia","volume":"14","author":"Richard-Carpentier G","year":"2019","unstructured":"Richard-Carpentier G, Kantarjian H, Jabbour E. Recent advances in adult acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2019;14(2):106\u201318. https:\/\/doi.org\/10.1007\/s11899-019-00503-1","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"e_1_3_10_4_2","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1148\/radiol.2020202858","article-title":"False-negative rates of breast cancer screening with and without digital breast tomosynthesis","volume":"298","author":"Durand MA","year":"2021","unstructured":"Durand MA, Friedewald SM, Plecha DM, . False-negative rates of breast cancer screening with and without digital breast tomosynthesis. Radiology. 2021;298(2):296\u2013305. https:\/\/doi.org\/10.1148\/radiol.2020202858","journal-title":"Radiology"},{"issue":"5","key":"e_1_3_10_5_2","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","article-title":"Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Hoelzer D","year":"2016","unstructured":"Hoelzer D, Bassan R, Dombret H, . Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v69\u201382. https:\/\/doi.org\/10.1093\/annonc\/mdw025","journal-title":"Ann Oncol"},{"issue":"1","key":"e_1_3_10_6_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40164-020-00170-6","article-title":"Leukemia incidence trends at the global, regional, and national level between 1990 and 2017","volume":"9","author":"Dong Y","year":"2020","unstructured":"Dong Y, Shi O, Zeng Q, . Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Exp Hematol Oncol. 2020;9(1):14. https:\/\/doi.org\/10.1186\/s40164-020-00170-6","journal-title":"Exp Hematol Oncol"},{"issue":"16","key":"e_1_3_10_7_2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger SP","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541\u201352. https:\/\/doi.org\/10.1056\/NEJMra1400972","journal-title":"N Engl J Med"},{"issue":"2","key":"e_1_3_10_8_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1200\/JOP.18.00271","article-title":"Acute lymphoblastic leukemia in the older adult","volume":"15","author":"Aldoss I","year":"2019","unstructured":"Aldoss I, Forman SJ, Pullarkat V. Acute lymphoblastic leukemia in the older adult. J Oncol Pract. 2019;15(2):67\u201375. https:\/\/doi.org\/10.1200\/JOP.18.00271","journal-title":"J Oncol Pract"},{"issue":"12","key":"e_1_3_10_9_2","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian H","year":"2004","unstructured":"Kantarjian H, Thomas D, O'Brien S, . Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101(12):2788\u2013801. https:\/\/doi.org\/10.1002\/cncr.20668","journal-title":"Cancer"},{"issue":"20","key":"e_1_3_10_10_2","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","article-title":"Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk b-acute lymphoblastic leukemia: a report from children's oncology group study AALL0232","volume":"34","author":"Larsen EC","year":"2016","unstructured":"Larsen EC, Devidas M, Chen S, . Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk b-acute lymphoblastic leukemia: a report from children's oncology group study AALL0232. J Clin Oncol. 2016;34(20):2380\u20138. https:\/\/doi.org\/10.1200\/jco.2015.62.4544","journal-title":"J Clin Oncol"},{"issue":"11","key":"e_1_3_10_11_2","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1200\/JCO.2007.13.7265","article-title":"Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96","volume":"26","author":"Ribera JM","year":"2008","unstructured":"Ribera JM, Oriol A, Sanz MA, . Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol. 2008;26(11):1843\u20139. https:\/\/doi.org\/10.1200\/JCO.2007.13.7265","journal-title":"J Clin Oncol"},{"issue":"3","key":"e_1_3_10_12_2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo DJ","year":"2015","unstructured":"DeAngelo DJ, Stevenson KE, Dahlberg SE, . Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29(3):526\u201334. https:\/\/doi.org\/10.1038\/leu.2014.229","journal-title":"Leukemia"},{"issue":"6","key":"e_1_3_10_13_2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study","volume":"27","author":"Huguet F","year":"2009","unstructured":"Huguet F, Leguay T, Raffoux E, . Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27(6):911\u20138. https:\/\/doi.org\/10.1200\/JCO.2008.18.6916","journal-title":"J Clin Oncol"},{"issue":"9","key":"e_1_3_10_14_2","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1200\/JCO.2013.50.2708","article-title":"Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia","volume":"32","author":"Douer D","year":"2014","unstructured":"Douer D, Aldoss I, Lunning MA, . Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia. J Clin Oncol. 2014;32(9):905\u201311. https:\/\/doi.org\/10.1200\/JCO.2013.50.2708","journal-title":"J Clin Oncol"},{"issue":"7","key":"e_1_3_10_15_2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/17474086.2020.1770591","article-title":"A review of current induction strategies and emerging prognostic factors in the management of children and adolescents with acute lymphoblastic leukemia","volume":"13","author":"Capria S","year":"2020","unstructured":"Capria S, Molica M, Mohamed S, . A review of current induction strategies and emerging prognostic factors in the management of children and adolescents with acute lymphoblastic leukemia. Expert Rev Hematol. 2020;13(7):755\u201369. https:\/\/doi.org\/10.1080\/17474086.2020.1770591","journal-title":"Expert Rev Hematol"},{"issue":"8","key":"e_1_3_10_16_2","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/leu.2011.84","article-title":"Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"25","author":"Teuffel O","year":"2011","unstructured":"Teuffel O, Kuster SP, Hunger SP, . Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leukemia. 2011;25(8):1232\u20138. https:\/\/doi.org\/10.1038\/leu.2011.84","journal-title":"Leukemia"},{"issue":"1","key":"e_1_3_10_17_2","doi-asserted-by":"crossref","first-page":"e0170259","DOI":"10.1371\/journal.pone.0170259","article-title":"Systematic review of the toxicity of long-course oral corticosteroids in children","volume":"12","author":"Aljebab F","year":"2017","unstructured":"Aljebab F, Choonara I, Conroy S. Systematic review of the toxicity of long-course oral corticosteroids in children. PLoS One. 2017;12(1):e0170259. https:\/\/doi.org\/10.1371\/journal.pone.0170259","journal-title":"PLoS One"},{"issue":"11","key":"e_1_3_10_18_2","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1002\/cncr.11390","article-title":"Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin","volume":"97","author":"Belgaumi AF","year":"2003","unstructured":"Belgaumi AF, Al-Bakrah M, Al-Mahr M, . Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin. Cancer. 2003;97(11):2898\u2013903. https:\/\/doi.org\/10.1002\/cncr.11390","journal-title":"Cancer"},{"issue":"1","key":"e_1_3_10_19_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu D","year":"2013","unstructured":"Liu D, Ahmet A, Ward L, . A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30. https:\/\/doi.org\/10.1186\/1710-1492-9-30","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"3","key":"e_1_3_10_20_2","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"e_1_3_10_21_2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.pedhc.2021.04.011","article-title":"PRISMA 2020: an update","volume":"35","author":"Swartz MK","year":"2021","unstructured":"Swartz MK. PRISMA 2020: an update. J Pediatr Health Care. 2021;35(4):351. https:\/\/doi.org\/10.1016\/j.pedhc.2021.04.011","journal-title":"J Pediatr Health Care"},{"issue":"1","key":"e_1_3_10_22_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4103\/0253-7184.69003","article-title":"Formulating a researchable question: a critical step for facilitating good clinical research","volume":"31","author":"Aslam S","year":"2010","unstructured":"Aslam S, Emmanuel P. Formulating a researchable question: a critical step for facilitating good clinical research. Indian J Sex Transm Dis AIDS. 2010;31(1):47\u201350. https:\/\/doi.org\/10.4103\/0253-7184.69003","journal-title":"Indian J Sex Transm Dis AIDS"},{"key":"e_1_3_10_23_2","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"e_1_3_10_24_2","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, . ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"e_1_3_10_25_2","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.1","author":"Higgins JPT","year":"2020","unstructured":"Higgins JPT, Thomas J, Chandler J, . Cochrane Handbook for Systematic Reviews of Interventions version 6.1. Cochrane Collaboration; 2020."},{"issue":"4","key":"e_1_3_10_26_2","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg CB","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088\u2013101. https:\/\/doi.org\/10.2307\/2533446","journal-title":"Biometrics"},{"issue":"7109","key":"e_1_3_10_27_2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger M","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"issue":"10","key":"e_1_3_10_28_2","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood-2002-08-2454","article-title":"Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group","volume":"101","author":"Bostrom BC","year":"2003","unstructured":"Bostrom BC, Sensel MR, Sather HN, . Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003;101(10):3809\u201317. https:\/\/doi.org\/10.1182\/blood-2002-08-2454","journal-title":"Blood"},{"issue":"4","key":"e_1_3_10_29_2","doi-asserted-by":"crossref","first-page":"pky069","DOI":"10.1093\/jncics\/pky069","article-title":"Validation of minimal residual disease as surrogate endpoint for event-free survival in childhood acute lymphoblastic leukemia","volume":"2","author":"Galimberti S","year":"2018","unstructured":"Galimberti S, Devidas M, Lucenti A, . Validation of minimal residual disease as surrogate endpoint for event-free survival in childhood acute lymphoblastic leukemia. JNCI Cancer Spectr. 2018;2(4):pky069. https:\/\/doi.org\/10.1093\/jncics\/pky069","journal-title":"JNCI Cancer Spectr"},{"issue":"27","key":"e_1_3_10_30_2","doi-asserted-by":"crossref","first-page":"6489","DOI":"10.1200\/JCO.2005.01.982","article-title":"No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol","volume":"23","author":"Igarashi S","year":"2005","unstructured":"Igarashi S, Manabe A, Ohara A, . No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol. J Clin Oncol. 2005;23(27):6489\u201398. https:\/\/doi.org\/10.1200\/jco.2005.01.982","journal-title":"J Clin Oncol"},{"issue":"4","key":"e_1_3_10_31_2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/mpo.2950190411","article-title":"Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia","volume":"19","author":"Jones B","year":"1991","unstructured":"Jones B, Freeman AI, Shuster JJ, . Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol. 1991;19(4):269\u201375. https:\/\/doi.org\/10.1002\/mpo.2950190411","journal-title":"Med Pediatr Oncol"},{"issue":"2","key":"e_1_3_10_32_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000339830","article-title":"Evaluation of adrenal reserve in children with acute lymphocytic leukemia treated with prednisone or dexamethasone","volume":"78","author":"Kuperman H","year":"2012","unstructured":"Kuperman H, Odone Filho V, Cristofani LM, . Evaluation of adrenal reserve in children with acute lymphocytic leukemia treated with prednisone or dexamethasone. Horm Res Paediatr. 2012;78(2):73\u201380. https:\/\/doi.org\/10.1159\/000339830","journal-title":"Horm Res Paediatr"},{"issue":"6","key":"e_1_3_10_33_2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2141.2005.05509.x","article-title":"Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial","volume":"129","author":"Mitchell CD","year":"2005","unstructured":"Mitchell CD, Richards SM, Kinsey SE, . Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol. 2005;129(6):734\u201345. https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05509.x","journal-title":"Br J Haematol"},{"issue":"17","key":"e_1_3_10_34_2","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood-2015-09-670729","article-title":"Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000","volume":"127","author":"M\u00f6ricke A","year":"2016","unstructured":"M\u00f6ricke A, Zimmermann M, Valsecchi MG, . Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood. 2016;127(17):2101\u201312. https:\/\/doi.org\/10.1182\/blood-2015-09-670729","journal-title":"Blood"},{"issue":"3","key":"e_1_3_10_35_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/01.mph.0000155870.38794.e7","article-title":"Steroid withdrawal syndrome during steroid tapering in childhood acute lymphoblastic leukemia: a controlled study comparing prednisone versus dexamethasone in induction phase","volume":"27","author":"Saracco P","year":"2005","unstructured":"Saracco P, Bertorello N, Farinasso L, . Steroid withdrawal syndrome during steroid tapering in childhood acute lymphoblastic leukemia: a controlled study comparing prednisone versus dexamethasone in induction phase. J Pediatr Hematol Oncol. 2005;27(3):141\u20134. https:\/\/doi.org\/10.1097\/01.mph.0000155870.38794.e7","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"e_1_3_10_36_2","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2001.19.4.1040","article-title":"Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia","volume":"19","author":"Schwartz CL","year":"2001","unstructured":"Schwartz CL, Thompson EB, Gelber RD, . Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol. 2001;19(4):1040\u20136. https:\/\/doi.org\/10.1200\/jco.2001.19.4.1040","journal-title":"J Clin Oncol"},{"issue":"11","key":"e_1_3_10_37_2","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/pbc.24666","article-title":"Neuropsychological outcomes of a randomized trial of prednisone versus dexamethasone in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute All Consortium Protocol 00-01","volume":"60","author":"Waber DP","year":"2013","unstructured":"Waber DP, McCabe M, Sebree M, . Neuropsychological outcomes of a randomized trial of prednisone versus dexamethasone in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute All Consortium Protocol 00-01. Pediatr Blood Cancer. 2013;60(11):1785\u201391. https:\/\/doi.org\/10.1002\/pbc.24666","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"e_1_3_10_38_2","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/(SICI)1097-0142(20000415)88:8<1964::AID-CNCR27>3.0.CO;2-1","article-title":"Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia","volume":"88","author":"Hurwitz CA","year":"2000","unstructured":"Hurwitz CA, Silverman LB, Schorin MA, . Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer. 2000;88(8):1964\u20139. https:\/\/doi.org\/10.1002\/(SICI)1097-0142(20000415)88:8<1964::AID-CNCR27>3.0.CO;2-1","journal-title":"Cancer"},{"issue":"11","key":"e_1_3_10_39_2","doi-asserted-by":"crossref","first-page":"e30571","DOI":"10.1002\/pbc.30571","article-title":"High burden of clinically significant adverse events associated with contemporary therapy for pediatric T-cell acute lymphoblastic leukemia\/lymphoma","volume":"70","author":"Summers RJ","year":"2023","unstructured":"Summers RJ, Monroig VM, DeGroote NP, . High burden of clinically significant adverse events associated with contemporary therapy for pediatric T-cell acute lymphoblastic leukemia\/lymphoma. Pediatr Blood Cancer. 2023;70(11):e30571. https:\/\/doi.org\/10.1002\/pbc.30571","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"e_1_3_10_40_2","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2008-12-186502","article-title":"A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia","volume":"114","author":"Kadan-Lottick NS","year":"2009","unstructured":"Kadan-Lottick NS, Brouwers P, Breiger D, . A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia. Blood. 2009;114(9):1746\u201352. https:\/\/doi.org\/10.1182\/blood-2008-12-186502","journal-title":"Blood"},{"issue":"12","key":"e_1_3_10_41_2","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1038\/sj.leu.2401973","article-title":"Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster","volume":"14","author":"Schrappe M","year":"2000","unstructured":"Schrappe M, Reiter A, Zimmermann M, . Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia. 2000;14(12):2205\u201322. https:\/\/doi.org\/10.1038\/sj.leu.2401973","journal-title":"Leukemia"},{"issue":"9","key":"e_1_3_10_42_2","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2012.43.2070","article-title":"Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study\u2013Dana-Farber Cancer Institute ALL Consortium Protocol 00-01","volume":"31","author":"Vrooman LM","year":"2013","unstructured":"Vrooman LM, Stevenson KE, Supko JG, . Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study\u2013Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013;31(9):1202\u201310. https:\/\/doi.org\/10.1200\/JCO.2012.43.2070","journal-title":"J Clin Oncol"},{"issue":"9","key":"e_1_3_10_43_2","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/S1470-2045(21)00328-4","article-title":"Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial","volume":"22","author":"Yang W","year":"2021","unstructured":"Yang W, Cai J, Shen S, . Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2021;22(9):1322\u201332. https:\/\/doi.org\/10.1016\/S1470-2045(21)00328-4","journal-title":"Lancet Oncol"},{"issue":"10","key":"e_1_3_10_44_2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/adc.2009.172528","article-title":"Skeletal morbidity in children receiving chemotherapy for acute lymphoblastic leukaemia","volume":"95","author":"Elmantaser M","year":"2010","unstructured":"Elmantaser M, Stewart G, Young D, . Skeletal morbidity in children receiving chemotherapy for acute lymphoblastic leukaemia. Arch Dis Child. 2010;95(10):805\u20139. https:\/\/doi.org\/10.1136\/adc.2009.172528","journal-title":"Arch Dis Child"},{"issue":"11","key":"e_1_3_10_45_2","first-page":"7","article-title":"Dexamethasone in induction can eliminate one third of all relapses in childhood acute lymphoblastic leukemia (ALL): results of an international randomized trial in 3655 Patients (Trial AIEOP-BFM ALL 2000)","volume":"112","author":"Schrappe M","year":"2008","unstructured":"Schrappe M, Zimmermann M, M\u00f6ricke A, . Dexamethasone in induction can eliminate one third of all relapses in childhood acute lymphoblastic leukemia (ALL): results of an international randomized trial in 3655 Patients (Trial AIEOP-BFM ALL 2000). Blood (ASH Annual Meeting Abstracts). 2008;112(11):7. https:\/\/doi.org\/10.1182\/blood.V112.11.7.7","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"22","key":"e_1_3_10_46_2","first-page":"321","article-title":"Dexamethasone and individualized asparaginase dosing are each associated with superior event-free survival in childhood acute lymphoblastic leukemia: results from DFCI-ALL Consortium Protocol 00-01","volume":"114","author":"Vrooman LM","year":"2009","unstructured":"Vrooman LM, Neuberg DS, Stevenson KE, . Dexamethasone and individualized asparaginase dosing are each associated with superior event-free survival in childhood acute lymphoblastic leukemia: results from DFCI-ALL Consortium Protocol 00-01. Blood (ASH Annual Meeting Abstracts). 2009;114(22):321. https:\/\/doi.org\/10.1182\/blood.V114.22.321.321","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"11","key":"e_1_3_10_47_2","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S1470-2045(10)70114-5","article-title":"Glucocorticoid use in acute lymphoblastic leukaemia","volume":"11","author":"Inaba H","year":"2010","unstructured":"Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010;11(11):1096\u2013106. https:\/\/doi.org\/10.1016\/s1470-2045(10)70114-5","journal-title":"Lancet Oncol"},{"issue":"1","key":"e_1_3_10_48_2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1182\/hematology.2022000337","article-title":"Optimal approach to T-cell ALL","volume":"2022","author":"O'Dwyer KM","year":"2022","unstructured":"O'Dwyer KM. Optimal approach to T-cell ALL. Hematology Am Soc Hematol Educ Program. 2022;2022(1):197\u2013205. https:\/\/doi.org\/10.1182\/hematology.2022000337C","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"e_1_3_10_49_2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/j.seminhematol.2013.06.007","article-title":"A 50-year journey to cure childhood acute lymphoblastic leukemia","volume":"50","author":"Pui CH","year":"2013","unstructured":"Pui CH, Evans WE. A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol. 2013;50(3):185\u201396. https:\/\/doi.org\/10.1053\/j.seminhematol.2013.06.007","journal-title":"Semin Hematol"},{"key":"e_1_3_10_50_2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jclinepi.2017.02.008","article-title":"Majority of systematic reviews published in high-impact journals neglected to register the protocols: a meta-epidemiological study","volume":"84","author":"Tsujimoto Y","year":"2017","unstructured":"Tsujimoto Y, Tsujimoto H, Kataoka Y, . Majority of systematic reviews published in high-impact journals neglected to register the protocols: a meta-epidemiological study. J Clin Epidemiol. 2017;84:54\u201360. https:\/\/doi.org\/10.1016\/j.jclinepi.2017.02.008","journal-title":"J Clin Epidemiol"}],"container-title":["Clinical and Investigative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/utppublishing.com\/doi\/pdf\/10.3138\/CIM-2025-0188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:43:59Z","timestamp":1784043839000},"score":1,"resource":{"primary":{"URL":"https:\/\/utppublishing.com\/doi\/10.3138\/CIM-2025-0188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,7,1]]}},"alternative-id":["10.3138\/CIM-2025-0188"],"URL":"https:\/\/doi.org\/10.3138\/cim-2025-0188","relation":{},"ISSN":["1488-2353"],"issn-type":[{"value":"1488-2353","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}